Moderna and Merck's mRNA melanoma vaccine extends cancer-free survival

Moderna and Merck announced this week that patients with melanoma who received their experimental mRNA vaccine alongside standard treatment lived longer without their cancer returning. The clinical trial results have been described as a potential game changer in oncology. The personalised vaccine works by training the immune system to recognise and attack tumour cells.